Efficacy and safety of hetrombopag in the treatment of chemotherapy-related thrombocytopenia in solid tumors: a retrospective study
The combination of hetrombopag and rhTPO therapy exhibits superior efficacy compared to monotherapy in the treatment of CIT in patients with solid tumors. This combination therapy is associated with rapid elevation of platelet counts and a shortened recovery period, while maintaining a favorable safety profile. Furthermore, hetrombopag monotherapy has shown efficacy comparable to that of rhTPO and recombinant human interleukin-11 (rhIL-11), thereby supporting its recommendation for clinical use.
Authors
- Qiang Tong (ORCID: https://orcid.org/0000-0003-0508-0727)
- Jiahui Liu (ORCID: https://orcid.org/0000-0002-9796-6463)
- Ye Kang (ORCID: https://orcid.org/0000-0002-6597-8005)
- Yuan Yuan (ORCID: https://orcid.org/0009-0002-9540-2100)
Institutions
- General Hospital of Shenyang Military Region (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-10-28
- DOI
- https://doi.org/10.3389/fonc.2025.1670029
- Primary Topic
- Platelet Disorders and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Department of Science and Technology of Liaoning Province